A syngeneic variance library for functional annotation of human variation: Application to BRCA2

Cancer Research

Volumn 68, Issue 13, 2008, Pages 5023-5030

  Hucl, Tomas ^a   Rago, Carlo ^b   Gallmeier, Eike ^a   Brody, Jonathan R ^a   Gorospe, Myriam ^c   Kern, Scott E ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLUTAMIC ACID; MITOMYCIN C; RAD51 PROTEIN; SERINE; ANTINEOPLASTIC AGENT; ETOPOSIDE; MITOMYCIN; RAD51 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CODON; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; GENE EXPRESSION; GENE FUNCTION; GENE LIBRARY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; BIOLOGICAL MODEL; CELL CLONE; CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENETICS; PHYSIOLOGY; RADIATION EXPOSURE; SITE DIRECTED MUTAGENESIS; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CHROMOSOMAL INSTABILITY; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE LIBRARY; GENES, BRCA2; HUMANS; MITOMYCIN; MODELS, BIOLOGICAL; MUTAGENESIS, SITE-DIRECTED; RAD51 RECOMBINASE; TUMOR STEM CELL ASSAY; VARIATION (GENETICS);

EID: 48549084778     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6189     Document Type: Article

References (38)

1. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
2. Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 2006;173:2187-98.
3. Davies AA, Masson JY, McIlwraith MJ, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001;7:273-82.
4. Esashi F, Christ N, Gannon J, et al. CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair. Nature 2005;434:598-604.
5. Wu K, Hinson SR, Ohashi A, et al. Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 2005;65:417-26.
6. Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999;59:3547-51.
7. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
8. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
9. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-90.
10. Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation. Nat Genet 1997;17:423-30.
11. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001;7:263-72.
12. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL. RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 1997;272:31941-4.
13. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997;386:804-10.
14. Gallmeier E, Kern SE. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models. Clin Cancer Res 2007;13:4-10.
15. Kohli M, Rago C, Lengauer C, Kinzler KW, Vogelstein B. Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses. Nucleic Acids Res 2004;32:e3.
16. Hurley PJ, Wilsker D, Bunz F. Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation. Oncogene 2007;26:2535-42.
17. Konishi H, Karakas B, Abukhdeir AM, et al. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 2007;67:8460-7.
18. Vogelstein B, Kinzler KW. Digital PCR. Proc Natl Acad Sci U S A 1999;96:9236-41.
19. Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale JL, Gorospe M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J 2004;23:3092-102.
20. Vindelov LL, Christensen IJ, Nissen NI. A detergenttrypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983;3:323-7.
21. Gallmeier E, Hucl T, Calhoun ES, et al. Gene-specific selection against experimental Fanconi anemia gene inactivation in human cancer. Cancer Biol Ther 2007;6:654-60.
22. Ikediobi ON, Davies H, Bignell G, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 2006;5:2606-12.
23. Wiegant WW, Overmeer RM, Godthelp BC, van Buul PP, Zdzienicka MZ. Chinese hamster cell mutant, V-C8, a model for analysis of Brca2 function. Mutat Res 2006;600:79-88.
24. Godthelp BC, van Buul PP, Jaspers NG, et al. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2. Mutat Res 2006;601:191-201.
25. Patel KJ, Yu VP, Lee H, et al. Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-57.
26. Kraakman-van der Zwet M, Overkamp WJ, van Lange RE, et al. Brca2 (XRCC11) deficiency results in radio-resistant DNA synthesis and a higher frequency of spontaneous deletions. Mol Cell Biol 2002;22:669-79.
27. Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol 1993;21:731-3.
28. Hucl T, Gallmeier E, Kern SE. Distinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials. Cell Cycle 2007;6:1336-41.
29. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
30. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
31. Gallmeier E, Winter JM, Cunningham SC, Kahn SR, Kern SE. Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX. Carcinogenesis 2005;26:1811-20.
32. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998;90:978-85.
33. Treszezamsky AD, Kachnic LA, Feng Z, Zhang J, Tokadjian C, Powell SN. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res 2007;67:7078-81.
34. Flores KG, McAllister KA, Greer PK, Wiseman RW, Hale LP. Thymic model for examining BRCA2 expression and function. Mol Carcinog 2002;35:103-9.
35. Hay T, Patrick T, Winton D, Sansom OJ, Clarke AR. Brca2 deficiency in the murine small intestine sensitizes to p53-dependent apoptosis and leads to the spontaneous deletion of stem cells. Oncogene 2005;24:3842-6.
36. Walker JV, Nitiss KC, Jensen LH, et al. A mutation in human topoisomerase IIa whose expression is lethal in DNA repair-deficient yeast cells. J Biol Chem 2004;279:25947-54.
37. Gallmeier E, Calhoun ES, Rago C, et al. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options. Gastroenterology 2006;130:2145-54.
38. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004;75:535-44.